From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades

Developing biomarkers for accurately predicting the efficacy of immune checkpoint inhibitor (ICI) therapies is conducive to avoiding unwanted side effects and economic burden. At the moment, the quantification of programmed cell death ligand 1 (PD-L1) in tumor tissues is clinically used as one of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xuan, Bao, Yulin, Meng, Bi, Xu, Zijian, Li, Sijin, Wang, Xu, Hou, Rui, Ma, Wen, Liu, Dan, Zheng, Junnian, Shi, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382880/
https://www.ncbi.nlm.nih.gov/pubmed/35990664
http://dx.doi.org/10.3389/fimmu.2022.920021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382880/
https://www.ncbi.nlm.nih.gov/pubmed/35990664
http://dx.doi.org/10.3389/fimmu.2022.920021

Ejemplares similares